# Endometrial Hyperplasia Management

> Endometrial hyperplasia management in NEET-PG Obstetrics and Gynaecology: atypia, LNG-IUS, progestins and surveillance.

- Canonical URL: https://prepelephant.com/topics/neet-pg/obstetrics-and-gynaecology/endometrial-hyperplasia-management
- Exam / course: NEET-PG · Subject: Obstetrics and Gynaecology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Endometrial Hyperplasia Management", PrepElephant, https://prepelephant.com/topics/neet-pg/obstetrics-and-gynaecology/endometrial-hyperplasia-management

## Direct answer

Endometrial hyperplasia means the endometrial glands have proliferated beyond normal under sustained unopposed oestrogen, and everything about its management flows from one question — is there cytological atypia? The WHO 2014 framework collapses the older four-tier scheme into non-atypical hyperplasia and atypical hyperplasia (endometrioid intraepithelial neoplasia). The prognostic split is stark: non-atypical hyperplasia progresses to carcinoma in only about 1-3 per cent, while untreated atypical hyperplasia harbours coexisting carcinoma in up to a third of hysterectomy specimens and progresses in a substantial minority — hence two diverging pathways. Hysterectomy is definitive for atypical hyperplasia in women who have completed childbearing; the levonorgestrel intrauterine system or oral progestogens for at least six months, with surveillance biopsy, is standard for non-atypical disease and for the young woman with atypia who desires fertility, alongside weight reduction and treatment of the oestrogen excess.

## What you must remember

- **Classification to quote:** WHO 2014 — non-atypical versus atypical hyperplasia/endometrioid intraepithelial neoplasia; the older simple/complex terminology is historical but still appears in Indian vivas.
- **Progression numbers:** non-atypical about 1-3 per cent over years; atypical hyperplasia progresses in a substantial proportion (older cohort figures near 30 per cent or more) and coexists with grade 1 carcinoma in up to a third of uteri — the argument for surgery.
- **Risk-factor engine:** unopposed oestrogen from obesity (peripheral aromatisation), PCOS and chronic anovulation, nulliparity, early menarche and late menopause, oestrogen-only therapy, tamoxifen, oestrogen-secreting tumours, Lynch syndrome.
- **Diagnosis:** endometrial sampling is mandatory — outpatient pipelle or dilatation and curettage with hysteroscopy when focal disease or architectural detail matters; transvaginal ultrasound supports but never replaces histology.
- **Non-atypical management:** LNG-IUS first line (regression above 80-90 per cent commonly quoted), or cyclic/continuous oral progestogens for three to six months, plus removing the drive — weight loss, treating anovulation, stopping unopposed oestrogen.
- **Atypical management:** hysterectomy with bilateral salpingo-oophorectomy when family is complete; fertility-sparing progestin therapy (LNG-IUS or high-dose oral) only in strictly counselled young women, with repeat sampling every six months until two consecutive negatives, and hysterectomy after childbearing.
- **Tamoxifen caution:** any abnormal bleeding on tamoxifen gets sampling; the hyperplasia it causes is often polypoid and atypical.
- **Lynch thread:** endometrial cancer is often the sentinel malignancy of Lynch syndrome — family history of colorectal and endometrial cancers in a young patient deserves genetics referral.

## A worked case with a fork

A 42-year-old with BMI 34, long-standing oligomenorrhoea and PCOS presents with six months of heavy irregular bleeding; pipelle sampling reports atypical hyperplasia. The consultation forks on fertility. With two children, she is counselled that a third or more of such uteri already harbour carcinoma and that total laparoscopic hysterectomy with bilateral salpingo-oophorectomy is guideline-concordant definitive treatment. If she deeply wants another child: hysteroscopy to exclude a focal carcinoma first, then LNG-IUS or high-dose oral progestin for six months, a weight-reduction programme, and repeat biopsy six-monthly until two consecutive negatives; conception is encouraged once regression is confirmed, and hysterectomy follows completed family. If she relapses twice, surgery stops being optional. Contrast her 53-year-old postmenopausal counterpart on tamoxifen with the same histology: her pathway is hysterectomy, because age plus tamoxifen plus atypia stacks the risk of concurrent carcinoma too high to watch.

## Where students slip

Three slips recur. First, treating all hyperplasia identically — prescribing progestins for atypical disease in a completed-family patient and forgetting surgery is the guideline answer. Second, quoting the old four-category classification as current and missing the atypia axis when asked how hyperplasia is classified today. Third, forgetting surveillance: progestin therapy without scheduled repeat sampling delays carcinoma diagnoses; the expected cadence is six-monthly biopsy until two consecutive negatives. A quieter slip: relying on ultrasound thickness for follow-up — regression is defined histologically, not sonographically.

## Frequently asked questions

### How does atypia change the management of endometrial hyperplasia?

Non-atypical disease is treated with progestogens (best via the levonorgestrel intrauterine system) and risk-factor correction, while atypical hyperplasia warrants hysterectomy when fertility is complete, with progestins reserved for selected fertility-seekers.

### What is the risk of progression with atypical hyperplasia?

Untreated atypical hyperplasia progresses in a substantial minority — commonly quoted around 30 per cent in older cohorts — and coexisting carcinoma is found in up to about a third of hysterectomy specimens.

### Which device gives the highest regression rates?

The levonorgestrel-releasing intrauterine system, delivering high local progestin with minimal systemic exposure, outperforming oral progestogens in comparative studies.

### How is a young woman with atypical hyperplasia who wants fertility managed?

Hysteroscopy to exclude carcinoma, then LNG-IUS or high-dose progestins with six-monthly sampling until two consecutive negative biopsies, weight loss, prompt conception, and hysterectomy once family is complete.

### Why does tamoxifen cause endometrial pathology?

Tamoxifen acts as a partial oestrogen agonist on the endometrium, producing polyps, hyperplasia and occasionally carcinoma, so abnormal bleeding on tamoxifen requires endometrial sampling.